By

Editor

Pablo L, Garay Aramburu G, García Layana A, Fernandez A, Vázquez I, Acebes X, Zulueta J, Balonga D, Salinas Ortega L , Muñoz A ,Casado Gómez A , Casado MA , Salvador J, Banon Rodriguez I, Ruiz Moreno JM

 

Assessing the economic burden of vision loss and irreversible legal blindness in Spain (2021–2030): a societal perspective
Health Econ Rev. 2024 Sep 3;14(1):70

Córdoba R, López-Corral L, Presa M, Martín-Escudero V, Vadgama S, Casado MÁ, Pardo C

 

 

The Health Impacts of Better Access to Axicabtagene Ciloleucel: The Case of Spain
Cancers. https://doi.org/10.3390/cancers16152712

Álvarez-Álvarez B, Prieto-Pérez L, de la Cuadra-Grande A, Casado MÁ, Cabello Úbeda A, Al-Hayani AW, Carrillo Acosta I, Mahillo-Fernández I, Górgolas Hernández-Mora M, Benito JM, Rallón N

 

The Era of DAAs: Assessing the Patients’ Characteristics, Clinical Impact, and Emergence of Comorbidities in HIV/HCV-Coinfected versus HIV-Infected Individuals
J. Clin. Med. 2024, 13, 3936

MÁS INFORMACIÓN

García-Sancho AM, Presa M, Pardo C, Martín-Escudero V, Oyagüez I, Ortiz-Maldonado V

 

 

Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain
Cancers 2024, 16, 2301